- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Differences in Leading Treatments for Heart Failure
A discussion on the differences of sacubitril-valsartan and spironolactone for the treatment of heart failure.
EP: 1.Heart Failure Clinical and Economic Burden
EP: 2.The Progressive Nature of Heart Failure
EP: 3.Link Between LVEF, NT-ProBNP and Cardiac Remodeling
EP: 4.Improved Understanding of Heart Failure
EP: 5.Treatment Goals for Patients With Heart Failure
EP: 6.The HFrEF Standard of Care
EP: 7.Heart Failure Management Unmet Needs
EP: 8.Utilization Management Strategies for Appropriate Treatment
EP: 9.Challenges in the Management of HFpEF
EP: 10.Differences in Standard of Care: HFpEF vs HFrEF
EP: 11.Ensuring Timely and Appropriate Access to Therapy
EP: 12.Differences in Economic Burden: HFpEF and HFrEF
EP: 13.PROVE-HF Trial Overview
EP: 14.PARAGON-HF Trial Overview
EP: 15.Recent Findings from the PARALLAX Study
EP: 16.Promising Findings From the TOPCAT Study
EP: 17.Differences in Leading Treatments for Heart Failure
EP: 18.When to Add an SGLT2 Inhibitor to Treatment Regimen
EP: 19.Heart Failure Sites of Care
EP: 20.How Approved Agents Will Change the Standard of Care
EP: 21.Heart Failure Management During COVID-19
John McMurray, MBChB: The 2 treatments that may be beneficial for at least in some patients with heart failure and preserved ejection fraction are sacubitril-valsartan and spironolactone. They are quite distinct, but they are also complementary. Sacubitril-valsartan is 2 drugs. Valsartan is an angiotensin receptor blocker that blocks the harmful effects of angiotensin 2 in the heart, the kidneys, and the blood vessels. Sacubitril is a neprilysin inhibitor. Neprilysin is an enzyme that breaks down natriuretic peptides and the other vasoactive substances. We believe that these are beneficial in heart failure, so if you inhibit the enzyme that breaks them down, you increase their levels, and we believe that those peptides bring about beneficial effects, stimulating the kidneys to excrete more sodium in water, thereby inhibiting pathological growth like fibrosis, mycotrophic, for example. On the other hand, spironolactone is a drug that blocks the action of corticosteroids, including aldosterone and its receptor. We believe that aldosterone is harmful in the kidneys and the heart; therefore, you could envision both treatments being used together. They do different things. One would anticipate that their benefits would be additive and incremental because they are in heart failure with reduced ejection fraction.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
Midodrine Use Linked to Decrease in HFrEF-Related ED Visits
March 23rd 2024However, researchers saw higher risks of respiratory failure, longer stays in the intensive care unit, increased hospitalizations, and elevated mortality rates in patients with heart failure with reduced ejection fraction (HFrEF) taking the antihypotensive medication.
Read More
